Capital Management, L.P.Ra ... Net Worth

The estimated Net Worth of Capital Management, L.P.Ra ... is at least $384 Million dollars as of 11 December 2023. Capital Ra owns over 1,000,000 units of iTeos Therapeutics stock worth over $307,040,124 and over the last 5 years Capital sold ITOS stock worth over $77,374,416.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Capital Ra ITOS stock SEC Form 4 insiders trading

Capital has made over 34 trades of the iTeos Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently Capital bought 1,000,000 units of ITOS stock worth $5,000,000 on 11 December 2023.

The largest trade Capital's ever made was buying 9,480,052 units of iTeos Therapeutics stock on 16 June 2022 worth over $20,382,112. On average, Capital trades about 580,607 units every 26 days since 2019. As of 11 December 2023 Capital still owns at least 19,202,009 units of iTeos Therapeutics stock.

You can see the complete history of Capital Ra stock trades at the bottom of the page.

Insiders trading at iTeos Therapeutics

Over the last 4 years, insiders at iTeos Therapeutics have traded over $196,492,023 worth of iTeos Therapeutics stock and bought 4,975,000 units worth $95,182,800 . The most active insiders traders include Capital Management, L.P.Ra ..., Capital Management, L.P.Kol..., and Aaron I. Davis. On average, iTeos Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $1,817,279. The most recent stock trade was executed by Matthew Gall on 12 October 2023, trading 5,000 units of ITOS stock currently worth $41,850.

What does iTeos Therapeutics do?

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Complete history of Capital Ra stock trades at Cidara Therapeutics Inc, Verastem Inc, Wave Life Sciences, Kala Bio, Rhythm Pharmaceuticals, scPharmaceuticals Inc, Solid Biosciences Inc, Iterum Therapeutics Plc, Orchard Therapeutics plc, Fulcrum Therapeutics Inc, Phathom Pharmaceuticals Inc, 89bio Inc, Imara Inc, Forma Therapeutics, Vaxcyte, Satsuma Pharmaceuticals, Nkarta, and iTeos Therapeutics

iTeos Therapeutics executives and stock owners

iTeos Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Michel Detheux Ph.D.,
  Pres, CEO & Director
• Dr. Michel Detheux,
  Pres, CEO & Director
• Dr. Joanne Jenkins Lager M.D.,
  Chief Medical Officer
• Matthew Gall,
  Chief Financial Officer
• Philippe Brantegem,
  Vice-Pres of HR
• Ryan Baker,
  Head of Investor Relations
• Matthew A. Call M.B.A.,
  Chief Operating Officer
• David Feltquate,
  Chief Medical Officer
• Bio Ventures 2014, L.P.Evni...,
  
• Capital Management, L.P.Kol...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Aaron I. Davis,
  
• Ann D Rhoads,
  
• Ansbert Gadicke,
  Director
• Derek Di Rocco,
  Director
• David Hallal,
  
• Detlev Biniszkiewicz,
  Director
• Capital, Llc Boxer Asset Ma...,
  
• Hauwermeiren Timothy Van,
  
• Ansbertubs Oncology Impact ...,
  
• Bio Ventures 2014, L.P.Mpm ...,
  
• Matthew Roden,
  Director
• Matthew Call,
  Chief Operating Officer
• Yvonne Mc Grath,
  Chief Scientific Officer
• Joanne Jenkins Lager,
  Chief Medical Officer
• Robert Iannone,
  
• Capital Management, L.P.Ra ...,
  
• Bio Ventures 2014, L.P.Evni...,
  
• Bioventures 2018, L.P.Mpm B...,
  
• Ansbertubs Oncology Impact ...,
  
• Ansbertubs Oncology Impact ...,
  
• Capital, Llc Boxer Asset Ma...,
  
• Capital, Llc Boxer Asset Ma...,
  
• David K Lee,
  
• Michel Detheux,
  Chief Executive Officer
• Matthew Gall,
  Chief Financial Officer
• Jill De Simone,
  
• Tony W Ho,